Who Is ELYXR? A Brand File on the Storefront Behind the Recall

ELYXR is a storefront you can shop from but not look behind. The website is polished, the catalog is enormous, and the company operating it is nowhere on the page. We identified JXK Enterprises, Inc. of Miami the way you'd identify a hit-and-run driver: from the records the outside world keeps, an FDA recall notice, a BBB profile, a Florida corporate filing. On a scorecard that measures disclosure, that inversion, where regulators and complaint boards know more about the company than its own customers can learn from its site, is close to a worst case.

But an F built carelessly would be worthless, so we built this one the way we built Diamond CBD's: every adverse item framed at its exact weight. The recall was voluntary, and no one is reported harmed. The lab is real and named, and we credit it. The FDA has never sent ELYXR a warning letter, and we checked every sweep, including the 2025 7-OH letters. What remains after all that fairness is still a 34: anonymity, potency-only panels, a hot COA on the company's own site, a false claim about FDA approval, and a recall for an undeclared prescription drug in a product it sold. Here is each piece, precisely.

Start with what the website tells you: the terms of service identify the operator only as 'elyxrstore.' No legal entity, no address of record, no people. The branding says 'ELYXR LA,' which points you to Los Angeles, and that's wrong too: the contact page (we archived it) shows a Miami, Florida address.

The actual company is JXK Enterprises, Inc., a Florida corporation, document number P22000014382 on the state registry. We know that not from elyxr.com but from three outside records that happen to agree: the FDA recall notice (which names JXK Enterprises as the recalling firm and elyxr.com as the distribution channel), the Better Business Bureau profile (filed under JXK Enterprises, Miami), and the Florida Division of Corporations filing itself. That filing yields the only human name in ELYXR's entire public record: Jacqueline Kazemi, the officer listed on the registration. We want to be careful here: the record supports 'officer listed on the state filing' and nothing more. We do not know whether she founded the company, runs it, or owns it, because none of that is disclosed, so we don't say it.

This is the anchor event of the file, and it deserves exact words, all of them.

• What happened: in May 2026, JXK Enterprises, Inc. conducted a voluntary nationwide recall of a product called 'Boner Bears Sex Chocolate' after testing found it contained undeclared sildenafil, the prescription drug in Viagra. The FDA publicized the recall on its safety-alerts page, and the notice names elyxr.com as the channel through which the product was distributed.
• Why it matters: undeclared sildenafil is a genuine safety issue, not a paperwork one. Sildenafil can interact dangerously with nitrates prescribed for heart conditions, which is why an unlabeled dose of it in a candy sold online is exactly the scenario recall systems exist for.
• The mitigants, which are real: the recall was voluntary, initiated by the company rather than ordered. Per the notice, no adverse events had been reported to date. And the chocolate may have been made by a third party: JXK is the recalling firm, which is not necessarily the manufacturer, and the record doesn't establish who actually produced it.

Here's the credit, and it's genuine: ELYXR posts real batch COAs from KCA Laboratories, a named, ISO-17025-accredited lab. A named accredited lab is the single most important feature of a testing program, plenty of higher-graded brands fail it, and it's why this pillar scores 13 rather than single digits.

Now the perimeter around that credit:

• The panels are potency-only. The COAs we reviewed report cannabinoid percentages and stop. No pesticides, no heavy metals, no residual solvents, no microbials, on a catalog heavy with vapes and converted cannabinoids, the product classes where contaminant panels matter most.
• There's no batch-lookup tool. Reports live on a lab-results page as posted PDFs; there's no way to key the batch on your package to its certificate, so you can't confirm the report matches the item in your hand.
• One of their own COAs is over the federal line. A COA posted on ELYXR's own site (we archived it) reports 0.330% total delta-9 THC, above the 0.3% threshold that defines federally lawful hemp. That is a factual observation from the company's own published document, one product, one batch, and we generalize it no further. But publishing a certificate that reads over the limit, apparently unnoticed, tells you how closely the lab-results page is being run.

The pattern is the same one the manufacturing pillar shows: a real ingredient of transparency (the named lab) embedded in a program with no scope, no verification path, and no evident review.

Three more pieces complete the record, and they cut in different directions.

• The 'FDA-approved facility' claim is false as stated. ELYXR's site says its products are made in an 'FDA-approved facility.' The FDA does not approve manufacturing facilities. It registers them, and it inspects them, but 'FDA-approved facility' is not a thing the agency issues to anyone. Whatever was meant, the statement as written asserts an approval that does not exist, on the website of a company that discloses no facility at all. We flag it as a false claim about FDA process, and it is most of why manufacturing scores 3.
• The complaint record is poor. The BBB rates JXK Enterprises an F, with 6 of 7 complaints unanswered, and the Trustpilot average sits at 3.4. Ignoring complaints isn't an allegation of wrongdoing; it's a disclosure behavior, and it matches the rest of the file.
• The clean entries, verified rather than assumed. ELYXR appears in no FDA warning-letter sweep we checked: not the delta-8 letters, not the copycat-food letters, and notably not the 2025 letters over 7-hydroxymitragynine (7-OH) products, a category ELYXR sells. One precision worth printing: a 7-OH warning letter that circulates in connection with this brand went to 'Dr. Smoke,' a retailer that stocks ELYXR products, not to ELYXR or JXK, and attributing it to ELYXR would be false. We also found no lawsuits and no California Prop 65 notices naming the company.

In our view, ELYXR is what our methodology exists to surface: a high-volume storefront whose customers know less about it than the FDA, the BBB, and the Florida Division of Corporations do. The F is not built on the recall alone, and it is not built on speculation. It's built on measured facts: an operating company never named on its own site, one human name in the entire public record, potency-only COAs with no batch verification and one over-threshold certificate posted by the company itself, a false claim about FDA approval, an unanswered complaint file, and a confirmed, FDA-publicized voluntary recall for an undeclared prescription drug, stated here with every mitigant it is entitled to: voluntary, no adverse events reported, possibly third-party-made.

We also printed the favorable record: a real ISO-17025 lab, no warning letters in any sweep including 7-OH, no lawsuits found, no Prop 65 notices. Fairness is what makes the 34 mean something. If you buy from ELYXR, you're trusting a supply chain no one has described, checked by panels that don't test for contaminants, sold by a company you'd need a recall notice to name. An F (34/100). The full methodology shows every point; if JXK Enterprises names itself on its site, publishes full panels with batch lookup, and corrects the FDA claim, we'll re-grade on those facts (see the notice below).